Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -41.98%. However, over the past six months, we’ve seen a weaker performance of 21.26%. The price of UNCY leaped by -18.31% over the last 30 days. And in the last five days, it has fallen by -19.85%.
In terms of market performance, Unicycive Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $1.49 on 04/08/24, and the lowest value was recorded at $0.20 on 08/13/24.
52-week price history of UNCY Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Unicycive Therapeutics Inc’s current trading price is -69.07% away from its 52-week high, while its distance from the 52-week low is 128.12%. The stock’s price range during this period has varied between$0.20 and $1.49. The Unicycive Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.71 million for the day, a figure considerably higher than their average daily volume of 1.05 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Unicycive Therapeutics Inc (UNCY) has experienced a quarterly decline of -40.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 55.16M and boasts a workforce of 22 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6200, with a change in price of -0.1292. Similarly, Unicycive Therapeutics Inc recorded 1,254,218 in trading volume during the last 100 days, posting a change of -21.90%.
UNCY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for UNCY stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.02.
UNCY Stock Stochastic Average
Unicycive Therapeutics Inc’s raw stochastic average for the past 50 days is presently 4.44%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 4.44%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 21.72% and 23.91%, respectively.
